Patents by Inventor Paul J. Durda

Paul J. Durda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS
    Publication number: 20120195855
    Abstract: The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN-? receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 2, 2012
    Applicant: CytoCure LLC
    Inventors: Paul J. Durda, James T. Kurnick, Ian S. Dunn
  • Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
    Patent number: 5562905
    Abstract: A chemically synthesized 15 amino acid peptide designated peptide 1-69, which has the sequence of amino acids numbers 308 to 322 (RIQRGPGRAFVTIGK) of the human immunodeficiency virus-1 (HIV-1) IIIB env-coded protein, was used to immunize animals. Peptide 1-69 elicited in immunized animals antibodies that block HIV proliferation and block HIV-induced cell fusion in cell culture.
    Type: Grant
    Filed: March 20, 1989
    Date of Patent: October 8, 1996
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: William R. Kenealy, Stephen R. Petteway, Paul J. Durda
  • Method for detecting carcinomatous and precarcinomatous colo-rectal disease
    Patent number: 4912031
    Abstract: A method for distinguishing between carcinomatous and/or precarcinomatous colo-rectal disease and histologically similar conditions due to diseases that are not carcinomatous or precarcinomatous comprising contacting colo-rectal tissue with an antibody that binds to blood group substance H and determining the presence of carcinomatous or precarcinomatous disease upon a finding of bound antibody, or the absence of such disease upon the finding of no bound antibody.
    Type: Grant
    Filed: October 23, 1987
    Date of Patent: March 27, 1990
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Carolyn C. Compton, Paul J. Durda
  • Monoclonal hybridoma antibody specific for a human epithelial antigen
    Patent number: 4814275
    Abstract: A monoclonal hybridoma antibody with specificity for an antigen that is present on tumors of epithelial origin; the cell line secreting said antibodies; a process for selecting the cell line; a diagnostic process for detecting the antigen and a therapeutic process for neutrailization of the angtigen.
    Type: Grant
    Filed: May 13, 1985
    Date of Patent: March 21, 1989
    Assignee: E.I. DuPont de Nemours and Company
    Inventors: Paul J. Durda, David J. Green, Marcia J. Stone, Dennis E. Vaccaro